Literature DB >> 9806042

Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment.

R S Wallis1, M Perkins, M Phillips, M Joloba, B Demchuk, A Namale, J L Johnson, D Williams, K Wolski, L Teixeira, R Dietze, R D Mugerwa, K Eisenach, J J Ellner.   

Abstract

Sputum quantitative culture, acid-fast smear, days-to-positive by BACTEC, and Mycobacterium tuberculosis antigen 85 complex were monitored during therapy in 42 patients with pulmonary tuberculosis (TB). By BACTEC, 4 patients were persistently positive on days 90-180, and treatment ultimately failed in 2 of these. Antigen 85 expression increased in subjects in whom disease persisted (persisters) from days 0 to 14 when the difference between persisters and nonpersisters was statistically significant (P = .002). Only antigen 85 complex values at day 14 suggested TB persistence at or after day 90. All subjects with day 14 antigen 85 complex values < 60 pg/mL responded rapidly to treatment and were cured. Of those with values > 60 pg/mL, in 33% TB persisted at or after day 90 and treatment failed in 17%. Biologic factors expressed early in therapy, not related to compliance or resistance, may exert a substantial influence on outcome. The antigen 85 complex is critical in cell wall biosynthesis and is induced by isoniazid in vitro. Its induction may represent an adaptive transition to a persistent state during therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806042     DOI: 10.1086/515701

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.

Authors:  R S Wallis; M Phillips; J L Johnson; L Teixeira; L M Rocha; E Maciel; L Rose; C Wells; M Palaci; R Dietze; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity.

Authors:  Ernestas Janulionis; Carolina Sofer; Stephan K Schwander; Denarra Nevels; Barry Kreiswirth; Elena Shashkina; Robert S Wallis
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

3.  Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.

Authors:  R Dietze; L Teixeira; L M Rocha; M Palaci; J L Johnson; C Wells; L Rose; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Demonstration of components of antigen 85 complex in cerebrospinal fluid of tuberculous meningitis patients.

Authors:  Rajpal S Kashyap; Karen M Dobos; John T Belisle; Hemant J Purohit; Nitin H Chandak; Girdhar M Taori; Hatim F Daginawala
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

5.  Combinatorial use of antibodies to secreted mycobacterial proteins in a host immune system-independent test for tuberculosis.

Authors:  C P Landowski; H P Godfrey; S I Bentley-Hibbert; X Liu; Z Huang; R Sepulveda; K Huygen; M L Gennaro; F H Moy; S A Lesley; M Haak-Frendscho
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

6.  Predicting the outcome of therapy for pulmonary tuberculosis.

Authors:  R S Wallis; M D Perkins; M Phillips; M Joloba; A Namale; J L Johnson; C C Whalen; L Teixeira; B Demchuk; R Dietze; R D Mugerwa; K Eisenach; J J Ellner
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

7.  Diagnostic markers for tuberculosis ascites: a preliminary study.

Authors:  Rajpal S Kashyap; Sonali M Saha; Khushboo J Nagdev; Sanjeevani S Kelkar; Hemant J Purohit; Girdhar M Taori; Hatim F Daginawala
Journal:  Biomark Insights       Date:  2010-08-25

Review 8.  Assessment of treatment response in tuberculosis.

Authors:  Neesha Rockwood; Elsa du Bruyn; Thomas Morris; Robert J Wilkinson
Journal:  Expert Rev Respir Med       Date:  2016-03-31       Impact factor: 3.772

9.  Immunologic evaluation and validation of methods using synthetic peptides derived from Mycobacterium tuberculosis for the diagnosis of tuberculosis infection.

Authors:  Zaida Araujo; Francesca Giampietro; María de los Angeles Bochichio; Andrea Palacios; Jenifer Dinis; Jaime Isern; Jacobus Henry de Waard; Elsa Rada; Rafael Borges; Carlos Fernández de Larrea; Angel Villasmil; Magnolia Vanegas; Jose Antonio Enciso-Moreno; Manuel Alfonso Patarroyo
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-04       Impact factor: 2.743

Review 10.  Confronting the scientific obstacles to global control of tuberculosis.

Authors:  Douglas B Young; Mark D Perkins; Ken Duncan; Clifton E Barry
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.